Clinical trials
Metastatic Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 482 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07744126RecruitingPhase 2
Combination drug therapy for head and neck cancer that has spread
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
Duarte, CaliforniaAges 18 years+ - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Bullhead City, ArizonaAges 18 years+ - NCT07667400RecruitingPhase 1/Phase 2
Docetaxel plus SX-682 for advanced head and neck or prostate cancer
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Bethesda, MarylandAges 18–120 - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT04220749RecruitingPhase 2
Radiation vs mouth surgery for HPV-negative throat cancer
This Phase 2 trial compares two standard cancer treatments—radiation or surgery through the mouth—for HPV-negative oropharyngeal throat cancer. It aims to find out which approach works better while keeping side effects and quality of life acceptable.
London, OntarioAges 18 years+ - NCT04973306RecruitingPhase 2/Phase 3
Chemo-immunotherapy before surgery versus chemo-radiation
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
ShanghaiAges 18–75 - NCT04161664RecruitingPhase 2
Chemo for metastatic vulvar cancer with carboplatin and paclitaxel
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
AmsterdamAges 18 years+ - NCT05740995Recruiting
New pre-op treatment for esophageal cancer using immunotherapy plus chemo
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02290145RecruitingPhase 2
Study of Cyclin D1–targeted chemotherapy before oral cancer surgery
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04894370RecruitingPhase 2
Trial tests immunotherapy plus chemotherapy and radiation for anal cancer
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
BesançonAges 18 years+ - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07869823RecruitingEarly Phase 1
Skin cancer treatment for head and neck
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
St Louis, MissouriAges 18 years+ - NCT04204837RecruitingPhase 2
Nivolumab for advanced skin squamous cell cancer
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
GrazAges 18 years+ - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT06399419RecruitingPhase 1
Study of CBM588 with immunotherapy for advanced kidney cancer
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
Duarte, CaliforniaAges 18 years+ - NCT07814287RecruitingPhase 2
New drug combo for advanced EGFR-positive head and neck cancer
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Guangzhou, GuangdongAges 18–70 - NCT07807163RecruitingPhase 2
Study of ficerafusp alfa with pembrolizumab for head and neck cancer
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Fort Myers, FloridaAges 18 years+ - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT07791745RecruitingPhase 2/Phase 3
Comparing treatments for advanced head and neck cancer
This trial tests a new combination of treatments for head and neck cancer that has returned or spread and can't be cured with local therapy. It compares a standard chemotherapy with or without an additional drug to see which is more effective and safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07768189RecruitingPhase 3
Testing CRB-701 for throat cancer that returned
This study tests an investigational drug called CRB-701 to see if it can help people with a certain type of throat cancer that has not responded to standard treatments. The trial compares CRB-701 to a doctor's choice of other available treatments.
Huntsville, AlabamaAges 18 years+ - NCT07751341RecruitingPhase 2
New drug with chemotherapy for advanced esophageal cancer
This study tests a new drug (SHR-9839) alone or combined with standard chemotherapy and another immunotherapy drug (adebrelimab) for advanced esophageal cancer. The goal is to see if this combination helps shrink tumors or slow cancer growth better than the standard treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05014464RecruitingPhase 2
Testing ALK-targeted pills for ALK-positive advanced squamous cancer
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Changsha, HunanAges 18 years+ - NCT05797415Recruiting
Check sentinel lymph node biopsy for several eye skin cancers
This trial studies whether a “sentinel lymph node biopsy” can better detect cancer spread in people with specific cancers of the eye surface and nearby tissues. It may help doctors find the right next treatment by learning whether lymph nodes are involved.
Roma, RomeAges 18–95
Hear when a new Metastatic Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic squamous cell carcinoma?
- Yes. Clin2 currently lists 482 recruiting metastatic squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Metastatic Laryngeal Squamous Cell Carcinoma
- Metastatic Oral Cavity Squamous Cell Carcinoma
- Metastatic Skin Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.